China’s serendipity-based method to drug discovery
One thing exceptional is going on in Chinese language biotech, and it’s occurring quick. The nation’s drug builders are studying to run — actually run — by way of scientific trials and regulatory approvals. In an business well-known for glacial timelines and billion-dollar budgets, China’s tempo feels virtually alien.
Chinese language firms are growing medicine quicker and cheaper than anybody else, together with the U.S. And whereas the early focus has been on copycat medicine and incremental enhancements, it’s potential that one thing extra profound would possibly emerge from that ecosystem: a brand new productive method of growing medicine.
For many years, the biotech business has been skilled to think about drug discovery as a strategy of target-based design: discover a organic goal, hit it with a molecule, take a look at it, refine it, repeat. The entire edifice of contemporary pharma is constructed on that logic.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
